Nacuity Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nacuity.com
Clinical Trials
3
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)PK and PD Study of NPI-001 and Cysteamine Bitartrate
Phase 1
Recruiting
- Conditions
- Cystinosis
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nacuity Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05994534
- Locations
- 🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia
NPI-002 Intravitreal Implant for the Delay of Cataract Progression
Phase 1
Recruiting
- Conditions
- Cataract
- Interventions
- Drug: NPI-002 Intravitreal Implant
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nacuity Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05026632
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nacuity Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT04355689
- Locations
- 🇦🇺
Queensland Eye Institute, Brisbane, Australia
🇦🇺CERA, Melbourne, Australia
🇦🇺Lions Eye Institute, Perth, Australia
News
No news found